KLOX Technologies reports on its interim results from its ongoing clinical studies on LumiHeal(TM) for the treatment of chronic wounds and postsurgical scarring

ID: 1460885
recent pressrelease next pressrelease

(Thomson Reuters ONE) -

Data presented at the 2016 World Union of Wound Healing Societies Congress

LAVAL, Quebec, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Today, clinical interim
results on KLOX Technologies (Klox) LumiHeal(TM) for the treatment of hard-to-
heal non-responsive chronic wounds and postsurgical scarring will be reported in
conjunction with the 2016 World Union of Wound Healing Societies (WUWHS)
Congress in Florence, Italy.

The Klox LumiHeal(TM) system is a first-in-class, proprietary, non-invasive,
non-thermal treatment that harnesses the power of fluorescence in the presence
of oxidants to treat serious skin and soft tissue disorders.

"We believe that LumiHeal(TM )can really make a significant difference in the
way we manage and treat acute and chronic wounds", stated Dr. Marco Romanelli,
MD, PhD, Associate Professor of Dermatology at the School of Medicine,
University of Pisa, and Chief of the Wound Healing Research Unit, and President
Elect of the World Union of Wound Healing Societies. "This is an area where an
unmet need remains, and with LumiHeal''s(TM)innovative approach, excellent safety
profile and effectiveness, it can help bridge that gap."

Professor Franco Bassetto, Head Clinic of Plastic Surgery Full Professor of
Plastic Surgery Chair and Residency Program of Plastic Reconstructive and
Aesthetic Surgery, University Hospital of Padova, Italy, will at 12:15 p.m.
(CEST) unveil interim results from the EUREKA study, which evaluated the real-
life use of LumiHeal(TM) in chronic wounds management.

Following Professor Bassetto''s presentation, Professor Andreas Nikolis, MD, MSc,
FRCSC, Plastic Reconstructive and Aesthetic Surgery, Associate Professor of
Plastic Surgery, Division of plastic surgery, University of Montreal, Canada,
will share interim findings comparing LumiHeal(TM) to silicone sheets in the
treatment of surgical wounds in the context of breast reductions.

"We are thrilled by the interim results of both studies and the high level of
satisfaction from patients and investigators. Due to its ease of use and
effectiveness, 95% of investigators involved in the chronic wound management
study, EUREKA, stated they would recommend LumiHeal(TM) to their colleagues",
said Dr. Michel Cimon, MD, Senior Vice President, Chief Medical and Science
Officer of KLOX Technologies. "Furthermore, the vast majority of patients that
completed the postsurgical scarring study to date, were more satisfied with the
use of LumiHeal(TM) with respect to ease of use and complexity of treatment."

Clinical interim results from EUREKA study on LumiHeal(TM )and chronic wounds

Professor Franco Bassetto will report interim study results on the evaluation of
real-life use of LumiHeal(TM) in Chronic Wounds Management. To date, results
include 33 patients who took part in the 100-patient EUREKA study. The full
study will conclude by the end of the year and data will be available in the
first half of 2017.

Investigators'' interim analysis indicate that the use of LumiHeal(TM) in the
treatment of pressure ulcers (PU), diabetic foot ulcers (DFU) and venous leg
ulcers (VLU) is safe, easy to administer and very well tolerated by the
subjects'' population. Compliance to the study visits was excellent.

The good tolerability and compliance profiles may be due to the positive action
on pain reduction observed during this study, especially in the VLU population,
along with efficacy.

Interim results support the excellent efficacy profile of LumiHeal(TM) in
promoting wound healing and wound bed preparation. These results point to the
capacity of this treatment to help chronic, hard-to-heal, non-responsive wounds
(PU, DFU, VLU) become responsive, as would acute wounds. Interim results show
17 patients with chronic wounds closed over the course of the treatment, while
two (2) were close to closing and three (3) others were ready to skin graft. An
additional six (6) patients of the 33 experienced a decrease in wound size
during the study period, but without meeting the criteria of full responders.

Once closed, no wound reopened during the two-week confirmation period. The very
low risk of wound breakdown or dehiscence was in line with the study treatment.
Exploratory endpoints showed the potential of the system to modulate the
inflammatory response during the wound healing process. Subjects'' quality of
life was improved in all enumerated sub-sections (social life, well-being and
physical symptoms), and Investigators also responded with a high level of
satisfaction. The very low occurrence of infections during the study period, and
especially the absence of infections with DFU wounds, suggests a positive
control of the wound biofilm.

Preliminary results on the impact of LumiHeal(TM) on postsurgical scarring

Professor Andreas Nikolis will report interim findings from a study comparing
LumiHeal(TM) to silicone sheets in the treatment of surgical wounds.
42 patients undergoing bilateral breast reductions were enrolled in this study.
One (1) breast incision was randomized to treatment with LumiHeal(TM) (treatment
initiated at seven (7) or 21-days post-surgery), while the contralateral breast
was treated with silicone gel sheeting alone for eight (8) weeks.

Preliminary results from 16 patients who have completed all required treatment
visits support an excellent safety profile across all patients with a
significant improvement in physician and patient reported outcomes. To date, no
severe adverse effects have been reported in the study, and reported adverse
effects are unlikely to be linked to the LumiHeal(TM) treatment.

At the end of the treatment period, the data to date show a lower proportion of
patients with red scars, as well as a greater proportion of patients reaching
normal pliability. Furthermore, a significantly greater proportion of patients
treated with LumiHeal(TM) have reached a normal scar height when compared to
silicone sheets treatment.

The full study will conclude by the end of 2016 and data will be available in
the first half of 2017.

Schedule of LumiHeal(TM) related events at 2016 WUWHS Congress

Today, Klox is hosting a Satellite Symposium on The Role of KLOX BioPhotonic
System in Wound Healing (September 28, 2016) from 12:15 p.m. to 1:45 p.m. (CEST)
in Hall RAFFAELLO. Oral presentations:

* Unmet Needs in Wound Healing
Chair: Prof. Luc Teot, Montpellier University Hospital FRANCE

* Wound Healing: "Very Intimate Process". The Science Behind the LumiHeal(TM)
Prof. Giovanni Scapagnini, Department of Medicine and Health Sciences,
University of Molise

* EUREKA ITALIA. The Evaluation of Real-Life Use of KLOX BioPhotonic System in
Chronic Wounds Management: a Reproducibility Study. Interim Results
Prof. Franco Bassetto, Head Clinic of Plastic Surgery Full Professor of
Plastic Surgery Chair and Residency Program of Plastic Reconstructive and
Aesthetic Surgery University Hospital of Padova

* Evolution of Photobiomodulation: Impact on Scarring
Prof. Andreas Nikolis,  MD, MSc, FRCSC, Plastic Reconstructive and Aesthetic
Surgery, Associate Professor of Plastic Surgery, Division of plastic
surgery, University of Montreal

Other relevant presentations and posters:

* BioPhotonic Therapy Applied to Pressure Ulcers: a New Therapeutic
Author: Dr. Alessandro Corsi
Upper Floor at Poster Area (PO217-ID1042.45)

* A New Technology "Soft Used" in the Treatment of Chronic Injuries:
BioPhotonic as Added Value in Wound Healing in Economic Evaluation
Authors : Dr. Sara Sandroni, Dr. Morena Mascalchi, Dr. Mirella Rossi
Upper Floor at Poster Area (PO496-ID10893.45)

* Photonic Treatment of Chronic Wounds
Authors: Dr. Elia Ricci, Dr. Monica Pittarello, Dr. Alberico Balbiano di
Colcavagno, Dr. Veronica Fess
At Hall RENAISSANCE at 8:25 a.m. (CEST) on Monday, September 26, 2016

* Lasers and Lights in Wound Healing
Chair: Dr. Nicola Zerbinati (Italy)
Co-Chairs: Dr. Marcello Monti (Italy), Dr. Matteo Tretti Clementoni (Italy)
Speakers: Dr. Steven Paul Nisticò (Italy), Dr. Marco Romanelli (Italy)
At Hall LEONARDO from 3:45 p.m. to 5:45 p.m. (CEST) on Tuesday, September
27, 2016.

About LumiHeal(TM)
The KLOX BioPhotonic LumiHeal(TM) is a first-in-class, proprietary, non-thermal
and non-invasive treatment solution that harnesses the power of fluorescence in
the presence of oxidants to treat serious skin and soft tissue disorders.
LumiHeal(TM) has received the CE mark for treatment of acute and chronic wounds.
It is comprised of a multi-LED light and a topical photo-converter gel
comprising light-capturing molecules (chromophores), which is applied on the
open wound. The illumination of the topical photo-converter gel with the multi-
LED light permits the synergistic effects of oxidants and photons (fluorescence)
to control biofilms, initiate healing and reduce pain, in a safe and efficient
manner. The treatment duration lasts only a number of minutes and is non-
abrasive, non-thermal, and has been reported to be comfortable for the patient.

About KLOX Technologies
Klox is a specialty pharmaceutical company focused on developing and
commercializing products based on its proprietary BioPhotonic technology
platform to address skin and soft tissue disorders. Klox is advancing its
programs as part of its multiple franchises focusing on indications across
Dermatology, Wound Care, and Oral Health. For more information and to consult
the abstracts, please visit www.kloxtechnologies.com

Forward Looking Statements
Certain statements contained in this newswire, other than statements of fact
that are independently verifiable at the date hereof, may constitute forward-
looking statements. Examples of such forward looking statements include those
regarding cosmetics and medical devices and medical applications and clinical
trials and the status and related results thereto, as well those regarding
continuing and further development and commercialization efforts. Such
statements, based as they are on the current analysis and expectations of
management, inherently involve numerous risks and uncertainties, known and
unknown, many of which are beyond Klox Technologies Inc.''s control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the medical, cosmetics and/or consumer goods industries,
changes in the regulatory environment in the jurisdictions in which Klox
Technologies Inc. does business, financial and commercial markets volatility,
fluctuations in costs, and changes to the competitive environment, as well as
other risks. Consequently, actual future results may differ materially from the
anticipated results expressed in the forward-looking statements. In the case of
forward-looking statements regarding investigational product candidates and
continuing and further development efforts, specific risks which could cause
actual results to differ materially from Klox Technologies Inc.''s current
analysis and expectations include: failure to demonstrate the safety,
tolerability and efficacy of our products, final and quality controlled
verification of data and the related analyses, and the expense and uncertainty
of obtaining regulatory approval.

For more information:
Roxanne Chaudier
Hill+Knowlton Strategies

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: KLOX Technologies Inc. via GlobeNewswire

More information:
http://www.pfeiffer-vacuum.com http://www.smaltagroup.ru/ http://www.admixglobal.com/ http://www.sopediting.com http:// http://www.cargotec.com http://www.ivu.com http:// http:// http://www.sentencemaker.org https://www.ic.gc.ca/ http://www.binder-world.

Keywords (optional):

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: hugin
print pressrelease  send to a friend  

Date: 09/28/2016 - 06:00
Language: English
News-ID 1460885
Character count: 1636
Firma: KLOX Technologies Inc.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: Laval


Number of hits: 59


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 437
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 122

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.